220
TL1A DRIVES ILC-MEDIATED GRANULOPOIESIS AND COLITIS ASSOCIATED CANCER
Date
May 18, 2024
Tracks
Related Products
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
SAFETY OF IMMUNOSUPPRESSION IN A PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH A HISTORY OF CANCER: THE SAPPHIRE REGISTRY
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
WOUND HEALING AFTER EPISIOTOMY AND CESAREAN SECTION AMONG WOMEN WITH IBD
Background: Women with inflammatory bowel disease (IBD) face the complexities of disease management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals with IBD persists due to concern for perianal disease and perineal trauma…
A CLINICAL SCORE FOR UC2CD, A NOVEL SUBGROUP IN INFLAMMATORY BOWEL DISEASES (IBD) WITH DISTINCT SEROLOGICAL, GENETIC AND CLINICAL FEATURES
BACKGROUND: Previously we identified that patients with initial diagnosis of Ulcerative Colitis (UC) but subsequently had a diagnosis change to Crohn’s Disease (CD) (UC2CD) are a unique IBD subgroup with distinct serological, genetic and clinical features, including non-response to anti-TNF treatme…


